Global Breast Cancer Monoclonal Antibodies Market 2016-2020

This market research report identifies players like F. Hoffmann-La Roche, Amgen, and Mylan to be the key vendors in the global breast cancer mAbs market. This research report also presents a detailed segmentation of the market by type (naked and conjugated mAbs), by end-users (hospitals and retail pharmacies), and by geography (the Americas, APAC, and EMEA).

Overview of the global breast cancer monoclonal antibodies (mAbs) market

Market research analysts at Technavio have predicted that the global breast cancer monoclonal antibodies (mAbs) market will grow at a CAGR of around 8% between 2016 and 2020.  The breast cancer monoclonal antibodies (mAbs) market is one of the fastest-growing segments of the global mAbs market and has gained major research significance among biotech and pharmaceutical companies due to the presence of high unmet needs in this area. Antibodies are increasingly becoming the best choice to treat cancers, including breast cancer. The use of antibody-drug conjugates (ADCs), including radioimmunotherapy and antibody-directed enzyme prodrug therapy, is increasing rapidly. ADCs are highly effective cytotoxic drugs linked to mAbs. These drugs have shown to be potent and efficient in treating breast cancer. This has propelled vendors to focus on novel technologies such as Seattle Genetics (SGEN), ImmunoGen (IMGN), and Immunomedics (IMMU). The rising use of these antibodies in drug development increases revenue generation in the breast cancer mAbs market, contributing to market growth.

The breast cancer mAbs market in APAC will witness a high growth rate during the forecast period due to the better market penetration of breast cancer mAbs and biosimilars in emerging economies, especially in Japan, Australia, India, South Korea, and China. The rising number of initiatives undertaken by major vendors to assist patients in these countries is a significant contributor to the rise in sales of breast cancer mAbs in these countries. Moreover, the growing awareness about breast cancer and the available treatment alternatives will also propel growth prospects for the market growth in APAC.

Competitive landscape and key vendors

The competitive environment in this market is likely to intensify in the coming years with the increase in technological innovations, product extensions, and an increase in the number of mergers and acquisitions. Several major pharmaceutical companies that are adopting these strategies are anticipated to grow inorganically during the forecast period and increase their revenue. The probability of vendors entering this market is high owing to the high market potential, however, the presence of highly stringent guidelines to manufacture breast cancer mAbs will restrict them.

Leading vendors in the market are -

• F. Hoffmann-La Roche
• Amgen
• Mylan

Other prominent vendors in the breast cancer mAbs market include Actavis, Array BioPharma, AstraZeneca, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celldex Therapeutics, Celltrion, Chugai Pharmaceutical, Daiichi Sankyo, DARA Biosciences, Eddingpharm, Eisai, Galena Biopharma, GlaxoSmithKline, Halozyme Therapeutics, Hospira, ImmunoGen, Immunomedics, MacroGenics, Merck, Novartis, Oncothyreon, Pfizer, ProStrakan, Puma Biotechnology, Seattle Genetics, Sun Pharmaceutical Industries, Synta Pharmaceuticals, and Teva Pharmaceuticals.

Segmentation by type of mAbs and analysis of the breast cancer mAbs market

• Naked mAbs
• Conjugated mAbs

During 2015, the naked mAbs dominated the breast cancer mAbs market and accounted for more than 91% of the total market share. Naked mAbs do not have a radioactive material or drug attached to them, and are the most commonly used mAbs. Though they work by attaching themselves to specific antigens, naked mAbs attach to diseased cells to act as a marker for the body’s own immune system to destroy them. Some of the approved naked mAbs by the US FDA include Herceptin (trastuzumab) and Avastin (bevacizumab).

Segmentation by end-users and analysis of the breast cancer mAbs market

• Hospitals
• Retail pharmacies

Retail pharmacies are the largest end-users of mAbs and occupied around 52% share of the overall market during 2015. Retail pharmacies also provide a large customer base for mAbs. Individuals with breast cancer require mAbs as a targeted therapy. This helps in the success of primary treatment and prevents relapse of the disease. These drugs can be easily obtained from retail pharmacies for use in hospital settings.

 Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global breast cancer mAbs market?
• What are the key market trends impacting the growth of the global breast cancer mAbs market?
• What are the challenges to market growth?
• Who are the key vendors in the global breast cancer mAbs market?
• What are the market opportunities and threats faced by the vendors in the global breast cancer mAbs market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global breast cancer mAbs market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Monoclonal Antibodies Market 2016-2020
• Global Cancer Immunotherapies Market 2016-2020
• Global Antibody Drug Conjugates Market 2016-2020